1949840-87-2
Chemical Structure
BCL-XL-IN-3
- CAS No.: 1949840-87-2
- Formula:C46H55N7O6S
- Molecular Weight:834.04
InChIKey: JDRWPKNPESVAQP-UOKWIRAPSA-N
SMILES: O[C@H](CO)CCNCCO[C@](C1)(C2)C[C@@](C[C@@]2(C3)C)(C[C@]13C)CN4C(C)=C(C(C=CC(N(CCC5=CC=C6)CC5=C6C(NC7=NC8=CC=CC=C8S7)=O)=N9)=C9C(O)=O)C=N4
Biological Activity: BCL-XL-IN-3 is a cell-impermeable BCL-XL inhibitor with a Ki of 16 pM. BCL-XL-IN-3 disrupts the critical hydrogen bond network via methylation of the nitrogen atom on the P2-binding amide bond, resulting in complete loss of cellular activity against BCL-XL. BCL-XL-IN-3 can be used in non-small cell lung cancer and cancer-related research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BCL-XL-IN-3 | BCL-XL-IN-3 is a cell-impermeable BCL-XL inhibitor with a Ki of 16 pM. BCL-XL-IN-3 disrupts the critical hydrogen bond network via methylation of the nitrogen atom on the P2-binding amide bond, resulting in complete loss of cellular activity against BCL-XL. BCL-XL-IN-3 can be used in non-small cell lung cancer and cancer-related research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Judd AS, et al. BCL-X-targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors. Science advances. 2024 Oct 04;10(40):eado7120. [Content Brief]
- [2]. Tao ZF, et al. Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same. WO2016094509 A1. 2016 Jun 16.
Keywords
